All In Biotech

Drug Trial Radar · NCT06627322

A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)

Registry Based Randomized Controlled Trial of Multiple Combination Strategies of Intensive Glycemic Control to Reduce a Composite of Macrovascular and Microvascular Events in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH Study)

Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 5,950 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,950

Planned (sponsor's estimate)

Start

Nov 21, 2024

Primary completion

Sep 30, 2029

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Kyu Chang WonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boryung Pharmaceutical Co., Ltd; Dong-A ST Co., Ltd.; HK inno.N Corporation; Daewoong Pharmaceutical Co. LTD.; Chong Kun Dang Pharmaceutical Corp.; Celltrion; Kakao Healthcare Corp.; Handok Inc.
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials. Potential risks of intensive glycemic control, such as hypoglycemia and weight gain, may partly contributed to the possible harms associated with this approach. Recent advances in diabetes management with development of newer antidiabetic drugs which minimize possible harms of intensive glycemic control as well as reduce cardiorenal risks enabled safer glycemic reduction. Thus, this randomized trial aims to evaluate the effects of near normalization of HbA1c with novel approaches on microvascular complications and cardiovascular outcomes in people with T2D.

Conditions

  • Type 2 Diabetes

Interventions

  • Dual-combination therapyDrug

    Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.

  • Triple-combination therapyDrug

    Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.

  • Dexcom G7, PastaDevice

    Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A composite of major adverse cardiovascular events (MACE) or diabetic microvascular eventsTime frame: 6-month, 1-, 2-, 3-, 4-year after enrollment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Yeungnam University Medical Center

    Daegu, South Korea · Not yet recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.